Stay updated on Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial
Sign up to get notified when there's something new on the Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial page.

Latest updates to the Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial page
- Check7 days agoChange DetectedThe page now presents the ClinicalTrials.gov record for a completed Phase 2 study of mepolizumab versus placebo for bullous pemphigoid, including study design, participant criteria, and outcome measures.SummaryDifference40%

- Check14 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide banner announces the NIH website transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” during the transition. The displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check42 days agoChange DetectedThe footer's ClinicalTrials.gov revision label updates from v3.7.0 to v3.7.1. The study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record, with the standard site header and footer visible. This indicates a permissions or server issue preventing the study content from loading.SummaryDifference17%

- Check63 days agoChange DetectedThe page’s revision identifier was updated from v3.6.6 to v3.7.0, indicating a newer version of the page.SummaryDifference0.1%

Stay in the know with updates to Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial page.